Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics

Antibody-based therapy has revitalized the world of cancer therapeutics since rituximab was first approved for the treatment of Non-Hodgkin’s Lymphoma. Monoclonal antibodies against cancer antigens have been successful strategies for only a handful of cancer types due to many reasons including lack...

Descripción completa

Detalles Bibliográficos
Autores principales: Runcie, Karie, Budman, Daniel R., John, Veena, Seetharamu, Nagashree
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154901/
https://www.ncbi.nlm.nih.gov/pubmed/30249178
http://dx.doi.org/10.1186/s10020-018-0051-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154901/
https://www.ncbi.nlm.nih.gov/pubmed/30249178
http://dx.doi.org/10.1186/s10020-018-0051-4

Ejemplares similares